SCHEMBL22981212

SCHEMBL22981212

CC(C)(C)OC(=O)N1CCc2ccc(Cc3cncc(C(=O)O)c3)cc2C1

nearest known ligand 0.54

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ NR1H2 P55055 1/20 0.54
▸ ESR2 Q92731 1/20 0.50
▸ MAPT P10636 2/20 0.39
▸ TMEM97 Q5BJF2 2/20 0.39
▸ SIGMAR1 Q99720 2/20 0.39
▸ CYP4F2 P78329 1/20 0.38
▸ CYP4A11 Q02928 1/20 0.38
▸ IGF1R P08069 1/20 0.38
▸ GPR119 Q8TDV5 2/20 0.38
▸ MAPK1 P28482 1/20 0.38
▸ AKR1C3 P42330 1/20 0.37
▸ HPGD P15428 2/20 0.37
▸ HTT P42858 1/20 0.37
▸ SMN1; SMN2 Q16637 1/20 0.37
▸ UCHL1 P09936 1/20 0.37
▸ HDAC1 Q13547 1/20 0.37
▸ DDB1 Q16531 1/20 0.37
▸ CRBN Q96SW2 1/20 0.37
▸ MPO P05164 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29388827 1.00 NR1H2 (0.54) NR1H2ESR2MAPTTMEM97SIGMAR1
SCHEMBL29390120 0.90 NR1H2 (0.53) NR1H2ESR2MAPTCYP4F2CYP4A11
SCHEMBL22982263 0.90 NR1H2 (0.53) NR1H2ESR2MAPTCYP4F2CYP4A11
SCHEMBL5170947 0.81 ESR2 (0.52) NR1H2ESR2MAPTGPR119HTT
SCHEMBL622590 0.80 NR1H2 (0.70) NR1H2ESR2MAPTTMEM97SIGMAR1
SCHEMBL29373737 0.80 NR1H2 (0.70) NR1H2ESR2MAPTTMEM97SIGMAR1
SCHEMBL22982207 0.79 PRMT5 (0.40) TMEM97SIGMAR1CYP4F2CYP4A11HPGD
SCHEMBL14812959 0.79 NR1H2 (0.66) NR1H2ESR2TMEM97SIGMAR1IGF1R
SCHEMBL12376466 0.79 NR1H2 (0.69) NR1H2ESR2MAPTTMEM97SIGMAR1
SCHEMBL1285596 0.79 NR1H2 (0.69) NR1H2ESR2MAPTTMEM97SIGMAR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230250080-A1 ENZYME INHIBITORS KALVISTA PHARMACEUTICALS LTD (GB) 2023-08-10 — — US disclosed
US-20230250080-A1 ENZYME INHIBITORS KALVISTA PHARMACEUTICALS LTD (GB) 2023-08-10 — — US disclosed
US-20230250080-A1 ENZYME INHIBITORS KALVISTA PHARMACEUTICALS LTD (GB) 2023-08-10 — — US disclosed
US-11613527-B2 Enzyme inhibitors KALVISTA PHARMACEUTICALS LIMITED (GB) 2023-03-28 — — US disclosed
EP-4010333-A1 PLASMA KALLIKREIN INHIBITORS Kalvista Pharmaceuticals Limited (GB) 2022-06-15 — — EP disclosed
US-20220048894-A1 ENZYME INHIBITORS KALVISTA PHARMACEUTICALS LIMITED (GB) 2022-02-17 — — US disclosed
WO-2021028645-A1 PLASMA KALLIKREIN INHIBITORS KALVISTA PHARMACEUTICALS LIMITED (GB) 2021-02-18 — — WO disclosed
WO-2021028645-A1 PLASMA KALLIKREIN INHIBITORS KALVISTA PHARMACEUTICALS LIMITED (GB) 2021-02-18 — — WO disclosed
WO-2021028649-A1 PLASMA KALLIKREIN INHIBITORS KALVISTA PHARMACEUTICALS LIMITED (GB) 2021-02-18 — — WO disclosed
WO-2021028649-A1 PLASMA KALLIKREIN INHIBITORS KALVISTA PHARMACEUTICALS LIMITED (GB) 2021-02-18 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230250080-A1 ENZYME INHIBITORS SERPINB1, KLKB1, SERPINE1 NR1H2 794/4885ESR2 2034/4885MAPT 3548/4885
US-11613527-B2 Enzyme inhibitors SERPINB1, KLKB1, SERPINE1 NR1H2 794/4885ESR2 2034/4885MAPT 3548/4885
US-20220048894-A1 ENZYME INHIBITORS SERPINB1, KLKB1, SERPINE1 NR1H2 794/4885ESR2 2034/4885MAPT 3548/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback